The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
TARGIT-B IORT Boost Blunts Distant Relapse in Young Patients With Breast Cancer
2
Ponatinib/Blinatumomab Regimen Improves EFS in Ph-Positive ALL
3
Using Radiotherapy Strategically Alongside CAR T, Bispecifics in Myeloma
4
Why KEYNOTE-B96 Succeeded Where Single-Agent Pembrolizumab Did Not
5